Overall gene alterations from swab acquired tumor samples (patients 2–30) is similar to landscape of TCGA cervical squamous cell carcinoma dataset.

(A) Ninety-four percent (1339/1430) of altered genes in baseline samples (defined as substitutions, insertions or deletions in gene) were also identified in the TCGA dataset, suggesting accurate identification of mutated genes related to cervical cancer. (B) The distribution of the top 30 most altered genes in study samples 2–30 and in TCGA(C) was also similar. (TIF)</p

Patient characteristics.

Patient characteristics.</p

Gene list with alteration type and frequency for all samples.

(CSV)</p

Top 50 gene alterations over time for 33 patients with all four-time points.

Heat map displaying the top 50 genes ranked by occurrence for 33 patients (132 samples) grouped by timepoint collection during chemoradiation.</p

Quality characteristics for samples by timepoint.

Quality characteristics for samples by timepoint.</p

Top 50 gene alterations over time for 70 patients with paired normals.

Heat map displaying the top 50 genes ranked by occurrence for 70 patients (216 samples) grouped by timepoint collection during chemoradiation.</p

Computational pipeline for whole exome sequencing data.

Workflow depicting preprocessing, variant calling and data analysis tools and parameters implemented to analyze WES data acquired from tumor DNA collected by cervical swab.</p

Lollipop plots showing mutation site, type, and frequency of canonical genes associated with cervical cancer pathogenesis for all samples.

(TIF)</p

CONSORT 2010 checklist of information to include when reporting a pilot or feasibility trial*.

(PDF)</p

Sample and sequencing quality control metrics and tumor purity estimates for each tumor sample.

(XLSX)</p